Those are all valid but as a first cut to returning to normalcy, we need at least one widely deployed rapid test solution. Those exist. The fastest way forwards is to license one and deploy it. It can be made here, you are just buying the intellectual property/research so you can save some time. If you want to keep working on alternates, you can, but the alternates are not cost is no object because they are just second line (although they may supersede the first solution if proven worthy). Saying we won't look at external solutions and are making our own from scratch is idiotic (and that appears to be the path that almost every country is following).